Clinical trials: Epidermis
Healthy Volunteers
Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection
This study was designed as a randomized, double-blind, parallelity-controlled study.Eighty-eight healthy male subjects (44 in each group) will be enrolled in this study.The aim of this clinical trial is to evaluate…
- Trial name
- NCT04820439
- Testing
- recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627), Perjeta ®
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Non-Small Cell Lung Cancer (NSCLC)
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung…
- Trial name
- OSTARA (NCT05801029)
- Testing
- Osimertinib, Amivantamab
- Where
- 28 sites in Hong Kong, Malaysia and 4 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Breast Cancer, Breast Adenocarcinoma
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
The purpose of this study is to determine the safety and tolerability of rebastinib when combined with antitubulin therapy with paclitaxel or eribulin in patients with advanced breast cancer.
- Conditions
- Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Recurrent Breast Carcinoma
- Trial name
- NCT02824575
- Testing
- Rebastinib, Paclitaxel, Eribulin Mesylate
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Montefiore Medical Center
NSCLC, EGF-R Positive Non-Small Cell Lung Cancer
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
Icotinib is a first-generation inhibitor of EGFR-tyrosine kinase inhibitor in patients with non-small-cell lung cancer (NSCLC). Here we will evaluate neoadjuvant Icotinib with chemotherapy prior to surgery, in patients with…
- Trial name
- NCT05132985
- Testing
- Icotinib, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Breast Cancer
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and…
- Trial name
- NCT03529110
- Testing
- Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1)
- Where
- 164 sites in United States, Australia and 13 more
- Volunteers
- 524 people
- Sponsor
- Daiichi Sankyo
Breast Neoplasms
A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting
The study is descriptive and aims to characterize the treatment patterns of advanced breast cancer in Poland in the real-world data setting.
- Trial name
- NCT05478590
- Where
- 19 sites in Poland
- Volunteers
- 440 people
- Sponsor
- Pfizer
Lung Neoplasms
Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
Lung cancer is the leading cause of cancer-related death worldwide and is well known to remain a major health problem. Non-small-cell lung cancer (NSCLC) constitutes more than 80% of all the cases of lung cancer.
- Trial name
- NCT01775943
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Ulsan University Hospital
Non Small Cell Lung Cancer
Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients
The objective is to investigate the correlation between smoking pattern and clinical efficacy of EGFR TKIs in male patients with locally advanced or metastasized non-small cell lung cancer of adeno histology who have failed 1st…
- Trial name
- NCT00922025
- Where
- 6 sites in Taiwan
- Volunteers
- 186 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor, Metastatic Breast Cancer
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
This is a multicenter, open label, nonrandomized, sequential dose escalation/dose ranging, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 alone and in combination…
- Trial name
- NCT04872166
- Testing
- BTX-A51
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- Edgewood Oncology Inc.
Metastatic Breast Cancer
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer who have previously failed endocrine therapy.
- Trial name
- NCT07071337
- Testing
- SKB264, Nab-paclitaxel, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 430 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Burn
Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Burn
Different medical treatments are available for treatment of skin burns such as skin grafts and silver sulfadiazine ointment. These treatments are used for second degree burn as routine technique in burns units.
- Trial name
- NCT03162367
- Testing
- Autologous epidermal cell suspension, Silver sulfadiazine ointment
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- SCARM Institute, Tabriz, Iran
Primary Breast Cancer
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3
The study should evaluate distribution of 99mTc-HE3-G3 in patients with primary HER2-positive and HER2-negative breast cancer. The primary objective are: 1.
- Trial name
- HE3-G3 (NCT04277338)
- Testing
- SPECT
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Breast Cancer Metastatic
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination…
- Trial name
- NCT05155566
- Where
- 2 sites in Argentina, United Kingdom
- Volunteers
- 847 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer, Brain Metastases
Central Nervous System(CNS) Efficacy of Dacomitinib
This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.
- Trial name
- NCT04675008
- Testing
- Dacomitinib
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Breast Cancer
An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants
This is a descriptive, prospective, observational and epidemiological study on participants recently diagnosed with breast cancer to evaluate the HER2 status by IHC and SISH procedures.
- Trial name
- NCT02535026
- Where
- 4 sites in Peru, Uruguay
- Volunteers
- 580 people
- Sponsor
- Hoffmann-La Roche
Epidermal Pigmented Lesions, Skin Toning
Evaluation of the 755nm Alexandrite Laser for Skin Toning and Epidermal Pigmented Lesions in Asian Skin Types
The purpose of this study is to assess treatment for facial skin toning and removal of epidermal pigmented lesions for Asian patients using the 755nm Alexandrite laser
- Trial name
- NCT01754246
- Testing
- 755nm Alexandrite Laser
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cynosure, Inc.
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have unresectable liver cancer and liver dysfunction.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00047346
- Testing
- erlotinib hydrochloride, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer(NSCLC)
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
This is an open-label, multicenter, single-arm, phase II interventional clinical trial evaluating efficacy and safety of Icotinib as neoadjuvant treatment in patients with IIIA- IIIB NSCLC with activating EGFR mutation in exon 19…
- Trial name
- NCT02820116
- Testing
- Icotinib
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Beijing Haidian Hospital
HER2 Gene Mutation, Advanced Solid Tumors
HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.
- Trial name
- RAD202 (NCT06824155)
- Testing
- 177Lu-RAD202
- Where
- 5 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
Malignant Neoplasm of Stomach, Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to find out whether either trastuzumab or the combination of trastuzumab and pertuzumab with standard chemotherapy shows more activity against gastro-oesophageal adenocarcinoma than standard…
- Conditions
- Malignant Neoplasm of Stomach, Malignant Neoplasm of Cardio-esophageal Junction of Stomach, Epidermal Growth Factor Receptor (EGFR) Protein Overexpression
- Trial name
- INNOVATION (NCT02205047)
- Testing
- Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab
- Where
- 48 sites in Belgium, Estonia and 11 more
- Volunteers
- 172 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.